3D Systems Corporation (DDD) Q2 2025 Earnings Call Transcript

3D Systems (DDD) reported a 16% year-over-year revenue decline in Q2 2025 to $95 million, primarily attributed to a challenging macro environment and a slowdown in customer CapEx spending due to tariff uncertainty. Despite this, the company saw an 8% sequential revenue increase from continuing operations, indicating stabilization. DDD is aggressively executing a cost restructuring plan, reducing non-GAAP operating expenses by 27% year-over-year to $47 million, and targeting over $85 million in annualized savings by mid-2026 to achieve positive cash flow in 2026. Key growth areas, including MedTech (up 13% year-over-year) and Aerospace & Defense (nearly doubled revenues), showed strong performance, complemented by a strengthened balance sheet following the divestiture of its Geomagic software platform and proactive debt refinancing.

Analysis

3D Systems (DDD) reported a challenging second quarter, with revenue declining 16% year-over-year to $95 million, a direct consequence of a broad-based slowdown in customer CapEx spending, which management attributes to global tariff uncertainty. Despite the headline contraction, underlying results showed signs of stabilization, with continuing operations growing 8% sequentially after adjusting for the $7 million impact from the divested Geomagic software business. Management is aggressively addressing the revenue shortfall through a comprehensive restructuring plan aimed at achieving over $85 million in annualized savings by mid-2026. This initiative is already yielding results, with non-GAAP operating expenses falling 27% year-over-year to $47 million, and a clear target to reach the low $40 million range by the end of 2025. The company's strategic focus is on achieving positive cash flow in 2026, even at current revenue levels. Amidst the restructuring, key growth verticals are demonstrating significant strength. The Aerospace and Defense business nearly doubled its revenue year-over-year, now representing an over $30 million annual business. Similarly, the newly defined MedTech segment grew 13% year-over-year, supported by strong demand for personalized medical devices. While the overall Healthcare unit was down 8%, this was primarily due to a difficult comparison in the Dental business from a large 2024 customer order. The recent U.S. launch of the NextDent Jetted Denture solution provides a new, tangible growth catalyst, targeting a market expected to reach $600 million by 2029. The balance sheet has been materially strengthened through the Geomagic sale and a proactive debt refinancing, providing the necessary liquidity to execute the turnaround.

Key Decisions for Investors

• Investors should view DDD as a turnaround story, where the primary thesis rests on management's ability to execute its aggressive cost-cutting plan to reach positive cash flow in 2026, effectively bridging the current macro-driven revenue weakness.
• Monitor sequential progress on the cost-reduction plan, specifically whether non-GAAP OpEx trends towards the low-$40 million quarterly target, as this is the most critical lever for achieving profitability at current revenue levels.
• The commercial ramp-up of the NextDent Jetted Denture solution and sustained double-digit growth in the MedTech and Aerospace segments are key near-term catalysts to track for evidence that the company's focused growth strategy is gaining traction.
• The primary risk remains a prolonged period of weak customer CapEx, as persistent tariff volatility could further delay equipment purchases and challenge the timeline for returning to profitability, even with successful cost controls.